Introduction: There is a dearth of surveillance data on clinical Campylobacter in South Africa, particularly in the private healthcare environment. We investigated the prevalence of resistance to first-line antibiotics used to treat campylobacterioses in clinical Campylobacter isolates from a private pathology laboratory. Methodology: Identification of the Campylobacter specific genes were confirmed by PCR. Minimum inhibitory concentrations were determined using the broth micro-dilution method against macrolides (erythromycin, azithromycin), fluoroquinolones (ciprofloxacin, gatifloxacin) and tetracycline. Results: Seventy-two Campylobacter isolates were identified by PCR, with 54 (75%) being classified as C. jejuni and 18 (25%) as C. coli. Of these, 11 (20.4%) C. jejuni and six (33.3%) C. coli strains were resistant to ciprofloxacin and three (7.41%) C. jejuni and three (16.7%) C. coli strains were resistant to gatifloxacin. The number of C. jejuni strains resistant to erythromycin and azithromycin was 17 (31.5%) and 36 (50%) respectively, while the resistance of C. coli strains to erythromycin and azithromycin were seven (38.9%) and 14 (77.8%) respectively. Resistance to tetracycline was detected in 10 (55.6%) C. coli and 14 (25.9%) C. jejuni strains. Conclusion: In the light of these resistant profiles, the lack of a South African Campylobacter surveillance program is of concern. Relatively high prevalence of resistance in clinical isolates of C. jejuni and C. coli to the fluoroquinolones, macrolides and tetracycline used in first line treatment is of great concern. The efficacy treating human campylobacteriosis should thus be revisited.
Introduction
Campylobacter species are the most prevalent and widespread enteric bacteria pathogens in both industrialized and developing countries [1] . It accounts for most cases of human gastrointestinal infections worldwide, causing 400-500 million cases of diarrhea each year [2] . In the European Union (EU) in 2008, 190 ,566 cases of campylobacteriosis was confirmed [3] , while in the United States (USA), an estimated 2.4 million incidents occur each year [4] . A total of 220,209 Campylobacter cases were reported and confirmed by the EU in humans in 2011, and 212,064 established cases in 2010 [5] . In developing countries, Campylobacter-related gastroenteritis rates are most common amongst children less than five years old [6] .
Campylobacter infection is primarily a zoonotic disease as it is a commensal of food animals, particularly poultry, which serves as the main reservoir for human infection [7] . Other sources of transmission, include water, milk, and food animal meat products [8] . The disease characteristics vary from watery, nonbloody, non-inflammatory diarrhea to a severe inflammatory diarrhea followed by abdominal pain and fever [9] . Amongst all the species of Campylobacter, Campylobacter jejuni subsp jejuni, Campylobacter coli, and Campylobacter lari are the most prevalent pathogens in human [10, 11] , with C. jejuni being responsible for 80-90% and C. coli for 5-10% infections in human [12] . Campylobacter spp, especially C. jejuni subsp. jejuni, has been linked to extensive intestinal infections, including gastrointestinal infections, myocarditis, hepatitis, meningitis, myelitis, pancreatitis, haemolytic-uraemia syndrome and secondary complications, such as Guillain-Barré syndrome [13] .
The recommended drugs for treating campylobacteriosis are macrolides (erythromycin, azithromycin and clarithromycin), amoxicillin, fluoroquinolones (ciprofloxacin) and tetracycline [14] . However, the emergence of antibiotic resistant strains poses a challenge in the management of Campylobacter infections. Isolates of C. jejuni and C. coli with resistance to various antimicrobial agents have been reported in both developed and developing countries [15] due to the extensive and unrestrained use of antibiotics especially in developing countries [16] . Fluoroquinolone use in food animals (administration in poultry flocks which is the main reservoir of Campylobacter spp.) may be associated with increases of resistant Campylobacter strains in human health care [12, 17] . The latter has been well documented in several countries [12, 18, 19] . Mechanism of fluoroquinolone resistance was found to be chromosomally mediated through mutation of the gyrA gene and parC gene while macrolides resistance in C. jejuni is through the 23S rRNA. Resistance to tetracycline in C. jejuni and C. coli has been found to be positioned on a transmissible plasmid encoding ribosomal protection gene [16] .
There is a dearth of surveillance data on clinical Campylobacter in South Africa, particularly in the private healthcare environment. We therefore investigated the prevalence of resistance to ciprofloxacin and erythromycin, as well as against newer antibiotics in these classes, viz., gatifloxacin, azithromycin and tetracycline in clinical Campylobacter isolates from a private pathology laboratory in South Africa.
Methodology

Sample collection
Ethical approval was granted by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (reference number BE084/14 
Species identification
The Campylobacter species were screened using conventional methods that included the catalase, oxidase and hippurate hydrolysis tests, according to the Cape Town protocol [20] . PCR was used to confirm species identifications using primer hipO for C. jejuni and putative aspartokinase for C. coli as indicated in Table 1 . DNA was extracted using a modified heat lysis method; briefly, a bacterial cell suspension was boiled for 10 minutes followed by freeze-thaw for five minutes and then centrifuged at 5000 rpm for 10 min. The supernatant was collected and stored at -40ºC until analysis. The concentration and purity of the DNA was determined spectrophotometrically using the Nanodrop ND-1000 Spectrometer (Thermo Scientific, Waltham, USA), and all samples had an A 260/280 ratio ranging from 1.7 to 2.1. PCR was performed using a ThermoCycler (Applied Biosystems, Foster City, USA), the primers 2.5µl and sample DNA (10ng) were added to dreamTaq DNA polymerase master mix (Thermo Scientific, Waltham, USA) to a final reaction volume of 50µl. The reaction template for all primers was the same, with an initial denaturation at 95 o C for 5 min and final elongation at 72 o C for 4 min, with 35 cycles of PCR. The PCR consisted of denaturation at 95 o C for 1 min, followed by annealing for 30s (temperature for each primer shown in Table 1 ), and 30s elongation at 72 o C [21] . The primer sequences primer hipO and putative aspartokinase with their annealing temperatures are shown in Table 1 .
Antibiotic susceptibility testing
The minimum inhibitory concentrations (MICs) were determined by broth micro-dilution, as recommended by the Clinical and Laboratory Standards Institute (CLSI) guidelines [22] . The samples were tested against macrolides (erythromycin and azithromycin) (Sigma-Aldrich, Steinheim, Germany), fluoroquinolones (ciprofloxacin (Fluka Analytical, Sigma-Aldrich Buchs, Steinheim, Germany) and gatifloxacin (DLD Scientific, Durban North, South Africa) in order to determine whether there was a significant difference between newer generations of the same antibiotic class and tetracycline (Fluka Analytical, Gillingham, UK). The two-fold dilution range of antibiotics was as follows: for ciprofloxacin and gatifloxacin 8 -0.003µg/ml, for erythromycin and azithromycin 128 -0.06µg/ml, and for tetracycline, 128 -0.06µg/ml. The bacterial inoculate was adjusted to a 0.5 McFarland, as recommended by CLSI guidelines [22] Minimum Inhibitory Concentration determinations were done in replicate. Breakpoints for ciprofloxacin (MIC ≤1), gatifloxacin (MIC ≤2), tetracycline (MIC ≤4), and erythromycin (MIC ≤8) were used, as described in the CLSI M100-S24 for Enterobaceriaceae [22] . Due to lack of breakpoint in the CLSI guideline, the breakpoint for azithromycin (MIC 0.5 for C. coli and 0.25 for C. jejuni) was used as described in "Clinical breakpoints, epidemiological cutoff (ECOFF) values and EUCAST disk diffusion methodology for Campylobacter jejuni and Campylobacter coli" [23] . Multidrug resistance was defined as resistance to all three of the antibiotics classes that the antibiotics represent i.e. fluoroquinolones, macrolides and tetracycline.
Amplification of resistance genes
The extracted DNA was used to detect the frequently encountered genes conferring resistance to ciprofloxacin, erythromycin and tetracycline. The presence of the tetO gene, which is responsible for tetracycline resistance and Thr-86-Ile mutations that are found in the quinolones resistance determining region (QRDR) of the gyrA gene in Campylobacter, were investigated. The presence of erythromycin resistance was also determined by detecting point mutations at position 2075 and 2074 in the V 23S rRNA gene, which are associated with high levels of resistance [12] . The presence of the multidrug efflux pumps was investigated, specifically the Campylobacter multidrug efflux gene B (gene Cj366c), which was determined using a primer for cmeB. PCR, and master mix conditions were carried out as previously reported, with a 25 µl final reaction volume being used [24] . The primer sequences and PCR conditions are shown in Table 1 .
Statistical analysis
Statistical analysis was undertaken using SPSS software (IBM version 23) to correlate demographic and susceptibility data. MIC50 and MIC90 values were determined using the MIC susceptibility values, and the two-tailed T tests were used to determine significance (p ≤ 0.01) in resistance between antibiotics originating from the same class. 
Sequencing
The gyrA and tetO genes were confirmed by sequencing 12% and 16% of the samples respectively (Inqaba Biotechnical Industries (Pty) Ltd., Pretoria, South Africa) and blasting on GENBank. Due to financial constraints, not all the samples were sequenced. Table 2 shows the age, sex and in-patient/outpatient status of the sample. Of the 72 stool samples collected from patients, who were aged one month to 70 years, the infection rate was higher among males at 46 (63.9%) than females at 26 (36.1%). In terms of age, the most infected where 28 (38.9%) infants and toddlers aged 0-2 year(s), followed by 14 (19.4%) young to mature adults aged 21-40 years as indicated in Table 2 . The majority of the samples were collected in spring; 34 (46.6%) and summer 16 (21.9%), with 15 (20.5%) isolated in winter and eight (11%) in autumn. Persons whose infections were severe enough to warrant hospitalization accounted for 36 (47.2%) of the patients.
Results
Clinical profile
Species distribution of Campylobacter by PCR
From the 72 Campylobacter isolates tested by PCR, 54 (75%) were identified as C. jejuni using the hipO gene, and 18 (25%) were identified as C. coli with the putative aspartokinase gene amplification.
Minimum inhibitory concentration (MIC)
MIC's of the isolates showed resistance to ciprofloxacin of 11 (20.4%) C. jejuni and six (33.3%) C. coli strains. In comparison, resistance to gatifloxacin was shown in three (7.41%) C. jejuni and three (16.7%) C. coli strains, albeit not significantly (p ≥ 0.557). Notably, the majority (MIC90) of the Campylobacter strains (C. jejuni and C. coli) presented MIC≤ 2 µg/ml for ciprofloxacin and gatifloxacin, indicating low-level resistance to fluoroquinolones. The number of C. jejuni strains resistant to erythromycin and azithromycin was 17 (31.5%) and 36 (50%) respectively. In addition, the numbers of C. coli strains resistant to erythromycin and azithromycin were seven (38.9%) and 14 (77.8%) respectively. The MIC90 of the Campylobacter against erythromycin and azithromycin were approximately 2-folds apart (≥ 32 µg/ml) and not significantly different on comparison (p ≥ 0.497). Resistance to tetracycline was detected in nearly a third of the samples, 24 (33.3 Table 3 .
Antibiotic resistance genes Table 4 shows the results of the common mutations conferring resistance to fluoroquinolones, tetracycline and macrolides in C. jejuni and C. coli as was found in this study. Frequency of common mutations conferring resistance to fluoroquinolones, tetracycline and macrolides in C. jejuni and C. coli. The quinolone resistance determining region (QRDR) of the gyrA of all the fluoroquinolone resistance strains showed a mutation at the Thr-86-Ile region. In addition, two isolates that were susceptible to ciprofloxacin with an MIC value of 0.5 µg/ml also showed mutations at this region. The transitional mutations A2075G and A2074C in the 23S rRNA gene were only amplified in seven (7) C. coli strains and one isolate of C. jejuni. All isolates resistant against tetracycline were shown to carry the tetO gene. Campylobacter multi-resistance gene B (cmeB) was amplified in 13 (18.1%) strains. The sequenced samples all showed similarity with known gyrA and tetO genes of Campylobacter jejuni and Campylobacter coli sequences in GenBank.
Discussion
Campylobacter spp. isolated from patients with diarrhea by a private pathology laboratory in South Africa was studied. In this study, the infection rate was higher in male than in female compared to a study by Samie et al with the female having the highest rate of 21.7% [19] . Campylobacter spp. has been identified as the etiologic agent in outbreak and sporadic cases of gastroenteritis and gastrointestinal infection in both developed and developing counties [18] . Although this sample size collected from each season was too small for any statically significant seasonal distribution study, it did provide an indication that Campylobacter is likely to be more prevalent in summer and spring, as also reported by Mason et al. [25] . The most predominant of the Campylobacter spp. was C. jejuni, which is responsible for most infections in humans [12] , as corroborated in this study, where the majority of Campylobacter isolates 54 (75%) were C. jejuni and 18 (25%) were C. coli. Similar C. jejuni to C. coli ratios (%) have been confirmed in studies from USA (66:2) [26] , in the United Kingdom (90:10) [27] and China (76:19) [28] . This ratio of C. jejuni and C. coli has further been affirmed in developing countries. A study This study indicated that there was a higher rate of infection in children less than 3 years of age. This is comparable to results obtained by Samie et al., in Vhembe District, South-Africa, who found a higher rate of infection in children less than two years (30.4%) [19] . A recent review article by Fletcher et al., showed that Campylobacter gastroenteritis is particularly common between children less than 5 years old, with an isolation rate of approximately 58% in developing countries [30] . Another study conducted in New Delhi, India, showed a peak incidence of 19% in children below one year of age [31] . Infants and preschool children with compromised immune systems are more prone to infection than adults, thus control programs targeting the eradication of infection due to Campylobacter should prioritize children.
Increasing antibiotic resistance in Campylobacter spp., isolated from both humans and animals, has become a substantial and significant public health concern in both developed and developing countries [18, 32] . While most Campylobacter infections are selflimiting, antibiotics may be prescribed in severe cases or in immunocompromised patients, with macrolides (erythromycin), fluoroquinolones (ciprofloxacin) and tetracycline are being recommended [33] . In Campylobacter, E. coli, and other Gram-negative bacteria, the fluoroquinolone mode of action is by interfering with DNA gyrase, a type II topoisomerase that catalyzes the negative supercoiling of relaxed or positively supercoiled, double-strand, covalently closed circular DNA [34] . Mutations in the gyrA gene of Gram-negative bacteria cause resistance to fluoroquinolones by altering the amino acid sequence near the putative active site of the gyrA protein. The main mechanism of ciprofloxacin resistance of Campylobacter spp. is the alteration of codon 86 from threonine to isoleucine in the gyrA of both C. jejuni and C. coli [18] . This was seen in the total number of gyrA genes subjected to sequencing.
A steady increase in fluoroquinolones, macrolides and tetracycline resistance has been observed in Campylobacter in South-Africa. Lastovica observed that ciprofloxacin resistance increased from 1.4% to 29%, and to erythromycin it increased from 3.4% to 7.2% in a study conducted in Cape Town from 1998 to 2005 [35] . Studies carried out in the Vhembe district, South-Africa, by Samie et al. also showed an increase in erythromycin resistance from 25% to 53% and in ciprofloxacin from 8% to 13% from 2002 to 2007 [19] . Our study showed a 23.6% resistance to ciprofloxacin and 8.3% to gatifloxacin. Although the newer antibiotic i.e. gatifloxacin (A new 8-methoxyfluoroquinolone), appeared to be more effective, a significance difference could not be shown in this study. The difference in the resistance rate of ciprofloxacin and gatifloxacin has also been reported by Hayward et al., with an MIC of 50% and 90% for gatifloxacin for 0.094 µg/ml and 4 µg/ml respectively, while that of ciprofloxacin was 0.19 µg/ml and ˃32 µg/ml [36] . This could be attributed to older fluoroquinolones having greater potency against gyrase than against topoisomerase IV in many Gramnegative bacteria, and greater potency against topoisomerase IV than against gyrase in many Grampositive bacteria. The newer quinolones seem to have a closely balanced activity against these enzymes [37] .
For erythromycin, 33.3% resistance was observed and 69.4% for azithromycin in the present study, with no significant difference between these two antibiotics that belong to the same class. This is higher than previously reported by Lastovia and Samie et al, and may be attributed to selection pressure from the increasing use of these antibiotics since 2007. Global rises in antibiotic resistance have been noted in the Danish Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP) report of 2012. Resistance as high as 35% to ciprofloxacin and 20% to tetracycline was evident in domestically-associated C. jejuni isolates [38] . In a study carried out in New Delhi, India, from September 2010 to April 2012, an increase in resistance of ciprofloxacin and erythromycin from 71.4% to 86.1% and 6.1% to 22.2% respectively compared to a formal study carried out in 2005 was observed [31] .
In recent years, tetracycline resistance has occurred among many pathogenic and nonpathogenic species of bacteria, and it is due to different tetracycline resistance (tet) genes. The efflux pump and ribosomal protection genes are the two most important mechanism of tetracycline resistance in various genera of bacteria, and acquiring new tetracycline resistance genes is mostly associated with mobile components, such as plasmids or transposons, which are often conjugative elements [39] . In Campylobacter spp., tetracycline resistance is primarily mediated by a ribosomal protection protein (tetO) that is transferred as plasmid-encoded gene or in the chromosome where it is not self-mobile [40] . A 27% increase in tetracycline resistance was observed by Samie et al. while our study found 33.3% resistance. However, the study population and demographics differ, and additional studies are needed to confirm the tetracycline resistance increase in clinical samples in South-Africa.
A developing trend is the occurrence of multiple drug-resistant strains of zoonotic pathogens causing infections in humans in various developed countries [12] . Multi resistant Campylobacter spp. in SouthAfrica was first reported in 2006 by Lastovica [35] . Our study showed minimal multi-resistance in three (4.2%) isolates that were resistant to more than one of the antibiotic agents. This is comparable with the result noted in DANMAP of 4% multi-resistance of domestic acquired infection of Campylobacter in humans [38] . Higher levels of multi-drug resistance have been reported, e.g. 44 .9% in Iran [41] and 86% in China [28] . Multi-resistance presents a risk to humans by limiting the therapeutic choice of antibiotics.
In conclusion, this study provides information on the prevalence of thermophilic Campylobacter spp. in private health sector in South-Africa. The antibiotic resistance profiles observed in clinical isolates of C. jejuni and C. coli to the fluoroquinolone, macrolides and tetracycline, which are often used as first line treatment is of concern. It is thus necessary to undertake continuous monitoring of both prevalence and molecular characteristics of antibiotic resistance to inform effective treatment regimens for Campylobacter infections.
